About Cornelius Enuezie
Cornelius Enuezie, founder of COZAREN GmbH, leverages more than 28 years of experience in biopharmaceutical and agrochemical patents and industry leadership—including roles at Novartis, IMS Health, Teva, and Clarivate—to strengthen and elevate your IP strategy.
Proven ability to utilise technical knowledge, business acumen, specialist patent search and competitive intelligence research skills to facilitate an excellent record of building effective licensing and patent monetisation programmes and supplementing the revenue-generating activities of biopharmaceutical organisations.
Qualifications
-
Doctorate in Business Administration (DBA)
-
Master of Laws (LLM) in Patent and Technology Law
-
Bachelor of Science degree in Industrial Chemistry
Connect on LinkedIn for insights and networking
Company Capabilities Overview
Patent and Competitive Intelligence Searches
We provide comprehensive patent and competitive intelligence services to support strategic IP and business decisions. Our capabilities include in-depth:
-
Novelty and patentability searches to support informed filing strategies
-
Validity and opposition searches to assess patent strength in enforcement or dispute contexts
-
Freedom-to-operate (FTO) analyses to identify potential infringement risks ahead of product launch or market entry
-
Landscape and trend analyses to map the IP terrain, benchmark competitors, and uncover whitespace opportunities
These insights play a critical role in shaping patent strategies and are essential to M&A, licensing, and investment due diligence. Our tailored approach equips legal teams, investors, and executives with the intelligence needed to mitigate risk and capitalize on emerging opportunities.
Due Diligence Support
We offer a one-stop solution for conducting high-quality due diligence in the biopharmaceutical sector—delivered in collaboration with experienced and specialist patent attorneys.
Our due diligence services cover the full IP lifecycle and are tailored to support:
-
Licensing and acquisition evaluations
-
Investment and partnership decisions
-
R&D collaborations and joint ventures
-
Regulatory and commercialization readiness assessments
By combining technical expertise with legal and strategic insight, we ensure stakeholders have a clear, risk-informed view of IP assets, liabilities, and opportunities.
Patent Portfolio Optimization & Business/Licensing Opportunity Identification
We help organizations unlock the full potential of their intellectual property by optimizing patent portfolios and identifying strategic business and licensing opportunities. Our approach empowers legal, investment, and executive teams to make data-driven, value-focused decisions.
​
Key services include:
-
Patent right enforcement through litigation or licensing in response to third-party infringement
-
Identification of licensing prospects, emerging markets, and R&D collaboration opportunities
-
Uncovering underutilized R&D and commercial assets within existing portfolios
-
Monetization of non-core patents via licensing, divestiture, or alternative financial mechanisms
-
Competitive intelligence (CI) analysis to guide strategic pruning and drive operational cost savings
-
Assessment of infringement and litigation risk to support proactive IP risk mitigation
-
Development of robust business cases for monetisation and licensing, aligned with antitrust regulations and corporate ethics.
-
This strategic IP management framework enables stakeholders to maximise return on innovation, mitigate risk, and align IP assets with broader business objectives.
AI-Integrated Biosequence Search Platforms
We design, develop, and manage advanced biosequence search platforms powered by state-of-the-art algorithms—including BLAST and Smith-Waterman—to support high-performance searches across both patent and non-patent biological data.
In close collaboration with experienced engineering partners, we build AI-integrated platforms that enable powerful, scalable, and intelligent search capabilities, including:
-
Protein and nucleotide sequence searches
-
CDR (complementarity-determining region) searches for both proteins and nucleotides
-
Motif-based searches with support for up to five mismatches
-
Hybrid searches combining sequence data with keyword-based filters
Our platforms are purpose-built to streamline complex bioinformatics workflows, delivering unmatched precision, scalability, and actionable insight for IP, R&D, and regulatory stakeholders.
Expertise and Achievements
Major career achievements include:
-
Identified 11 patent infringement cases that generated over US$200 million in value for Novartis.
-
Led the execution of patent out-licensing initiatives, resulting in US$650 million in royalties and cost savings for Novartis.
-
Conducted in-depth competitive intelligence that directly influenced Clarivate’s strategic acquisition of SequenceBase.
-
Oversaw the post-acquisition integration of SequenceBase with Derwent Innovation, streamlining customer workflows and driving a 10%+ increase in new subscriptions.
-
Directed the integration of SequenceBase with Clarivate’s Life Science databases, enriching patented biosequence data with value-added commercial, clinical, regulatory, agrochemical, and plant biotechnology insights.